JP2023529570A5 - - Google Patents
Info
- Publication number
- JP2023529570A5 JP2023529570A5 JP2022571212A JP2022571212A JP2023529570A5 JP 2023529570 A5 JP2023529570 A5 JP 2023529570A5 JP 2022571212 A JP2022571212 A JP 2022571212A JP 2022571212 A JP2022571212 A JP 2022571212A JP 2023529570 A5 JP2023529570 A5 JP 2023529570A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- disease
- tautomer
- deficiency
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2008401.8A GB202008401D0 (en) | 2020-06-04 | 2020-06-04 | Novel compounds |
| GB2008401.8 | 2020-06-04 | ||
| GB2016689.8 | 2020-10-21 | ||
| GBGB2016689.8A GB202016689D0 (en) | 2020-10-21 | 2020-10-21 | Novel compounds |
| GBGB2101935.1A GB202101935D0 (en) | 2021-02-11 | 2021-02-11 | Novel compounds |
| GB2101935.1 | 2021-02-11 | ||
| PCT/EP2021/064897 WO2021245186A1 (en) | 2020-06-04 | 2021-06-03 | N-cyanopyrrolidines with activity as usp30 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529570A JP2023529570A (ja) | 2023-07-11 |
| JP2023529570A5 true JP2023529570A5 (https=) | 2025-10-30 |
| JP7796047B2 JP7796047B2 (ja) | 2026-01-08 |
Family
ID=76421953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022571212A Active JP7796047B2 (ja) | 2020-06-04 | 2021-06-03 | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230303547A1 (https=) |
| EP (1) | EP4161920A1 (https=) |
| JP (1) | JP7796047B2 (https=) |
| KR (1) | KR20230019198A (https=) |
| CN (1) | CN115698001A (https=) |
| AU (1) | AU2021285130A1 (https=) |
| BR (1) | BR112022019722A2 (https=) |
| CA (1) | CA3185654A1 (https=) |
| CO (1) | CO2022017112A2 (https=) |
| IL (1) | IL298710A (https=) |
| MX (1) | MX2022015254A (https=) |
| WO (1) | WO2021245186A1 (https=) |
| ZA (1) | ZA202213866B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024544660A (ja) | 2021-12-01 | 2024-12-03 | ミッション セラピューティクス リミティド | Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン |
| GB202408928D0 (en) | 2024-06-21 | 2024-08-07 | Mission Therapeutics Ltd | Novel compounds |
| GB202411060D0 (en) | 2024-07-29 | 2024-09-11 | Mission Therapeutics Ltd | Novel compounds |
| CN119528901A (zh) * | 2024-11-05 | 2025-02-28 | 上海市同济医院 | 噻唑类化合物、去sumo和/或去泛素化酶抑制剂及其制备方法和应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| EP1272467A4 (en) | 2000-04-06 | 2003-05-07 | Merck Frosst Canada Inc | Cathepsin cysteine protease inhibitors |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| SG174050A1 (en) | 2006-04-13 | 2011-09-29 | Actelion Pharmaceuticals Ltd | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| TWI433677B (zh) | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| US20090264431A1 (en) | 2007-08-20 | 2009-10-22 | Palovich Michael R | Novel cathepsin c inhibitors and their use |
| WO2009129371A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129370A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| WO2009129365A1 (en) | 2008-04-18 | 2009-10-22 | Glaxo Group Limited | Cathepsin c inhibitors |
| US20120309820A1 (en) | 2011-06-04 | 2012-12-06 | Jb Therapeutics Inc. | Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids |
| EP2565186A1 (en) | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| RS58361B1 (sr) | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| US9963444B2 (en) | 2014-05-19 | 2018-05-08 | Northeastern University | N-acylethanolamine hydrolyzing acid amidase (NAAA) inhibitors and their use thereof |
| US20170095457A1 (en) | 2014-05-27 | 2017-04-06 | David Lonergan | Compositions and methods of delivery of deubiquitinase inhibitors |
| WO2016019237A2 (en) | 2014-07-31 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| GB201416754D0 (en) | 2014-09-23 | 2014-11-05 | Mission Therapeutics Ltd | Novel compounds |
| CA2976741C (en) * | 2015-03-30 | 2023-01-17 | Mission Therapeutics Limited | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| WO2017009650A1 (en) | 2015-07-14 | 2017-01-19 | Mission Therapeutics Limited | Cyanopyrrolidines as dub inhibitors for the treatment of cancer |
| GB201521109D0 (en) | 2015-11-30 | 2016-01-13 | Mission Therapeutics Ltd | Novel compounds |
| GB201522267D0 (en) | 2015-12-17 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201522768D0 (en) | 2015-12-23 | 2016-02-03 | Mission Therapeutics Ltd | Novel compounds |
| GB201602854D0 (en) | 2016-02-18 | 2016-04-06 | Mission Therapeutics Ltd | Novel compounds |
| GB201603779D0 (en) | 2016-03-04 | 2016-04-20 | Mission Therapeutics Ltd | Novel compounds |
| GB201604647D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| GB201604638D0 (en) | 2016-03-18 | 2016-05-04 | Mission Therapeutics Ltd | Novel compounds |
| CN108884068B (zh) | 2016-03-24 | 2021-02-26 | 特殊治疗有限公司 | 作为dub抑制剂的1-氰基-吡咯烷衍生物 |
| US11014912B2 (en) | 2016-09-27 | 2021-05-25 | Mission Therapeutics Limited | Cyanopyrrolidine derivatives with activity as inhibitors of USP30 |
| GB201616511D0 (en) | 2016-09-29 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| GB201616627D0 (en) | 2016-09-30 | 2016-11-16 | Mission Therapeutics Limited | Novel compounds |
| TWI771327B (zh) | 2016-10-05 | 2022-07-21 | 英商使命醫療公司 | 新穎化合物 |
| US10968172B2 (en) | 2017-05-15 | 2021-04-06 | Mitobridge, Inc. | USP30 inhibitors |
| GB201708652D0 (en) | 2017-05-31 | 2017-07-12 | Mission Therapeutics Ltd | Novel compounds and uses |
| GB2563595B (en) | 2017-06-19 | 2020-04-15 | Edwards Ltd | Twin-shaft pumps |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| GB2571731A (en) | 2018-03-06 | 2019-09-11 | Mission Therapeutics Ltd | Novel compounds and uses |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| US11572374B2 (en) | 2018-08-14 | 2023-02-07 | Amgen Inc. | N-cyano-7-azanorbornane derivatives and uses thereof |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
| GB201905375D0 (en) | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201905371D0 (en) * | 2019-04-16 | 2019-05-29 | Mission Therapeutics Ltd | Novel compounds |
| GB201912674D0 (en) | 2019-09-04 | 2019-10-16 | Mission Therapeutics Ltd | Novel compounds |
-
2021
- 2021-06-03 US US18/007,641 patent/US20230303547A1/en active Pending
- 2021-06-03 EP EP21731947.4A patent/EP4161920A1/en active Pending
- 2021-06-03 IL IL298710A patent/IL298710A/en unknown
- 2021-06-03 CN CN202180038498.9A patent/CN115698001A/zh active Pending
- 2021-06-03 CA CA3185654A patent/CA3185654A1/en active Pending
- 2021-06-03 MX MX2022015254A patent/MX2022015254A/es unknown
- 2021-06-03 WO PCT/EP2021/064897 patent/WO2021245186A1/en not_active Ceased
- 2021-06-03 KR KR1020237000160A patent/KR20230019198A/ko active Pending
- 2021-06-03 BR BR112022019722A patent/BR112022019722A2/pt unknown
- 2021-06-03 AU AU2021285130A patent/AU2021285130A1/en active Pending
- 2021-06-03 JP JP2022571212A patent/JP7796047B2/ja active Active
-
2022
- 2022-11-29 CO CONC2022/0017112A patent/CO2022017112A2/es unknown
- 2022-12-21 ZA ZA2022/13866A patent/ZA202213866B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023529570A5 (https=) | ||
| JP2022546717A5 (https=) | ||
| CN109790112B (zh) | 具有作为usp30抑制剂活性的氰基吡咯烷衍生物 | |
| AP813A (en) | Urea derivatives as inhibitors of IMPDH enzyme. | |
| AU2011210567B2 (en) | Small molecules for the modulation of MCL-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders | |
| JP2023527025A5 (https=) | ||
| ES3062289T3 (en) | Factor xiia inhibitors | |
| JP2020189882A (ja) | Ｍｅｋインヒビターおよびその使用方法 | |
| JP2019501142A5 (https=) | ||
| CN104334556B (zh) | 新型1‑磷酸鞘氨醇受体拮抗剂 | |
| JP2023520727A5 (https=) | ||
| JP2019501142A (ja) | Ｕｓｐ３０の阻害剤としての１−シアノピロリジン誘導体 | |
| AU2017254523A1 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP2019503362A5 (https=) | ||
| JP2020512298A5 (https=) | ||
| JP2023528087A5 (https=) | ||
| KR20150000866A (ko) | 글루타미나제의 헤테로사이클릭 억제제 | |
| JP2013531029A (ja) | 化合物 | |
| WO2010115836A4 (en) | Substituted piperidines as ccr3 antagonists | |
| JP2013513615A (ja) | 脂肪酸アミドヒドロラーゼのアゾ環状阻害薬 | |
| JP7796047B2 (ja) | Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン | |
| HRP20250891T1 (hr) | 1-(5-(2-cijanopiridin-4-il)oksazol-2-karbonil)-4-metilheksahidropirolo[3,4-b]pirol-5(1h)-karbonitril kao usp30 inhibitor za primjenu u liječenju mitohondrijske disfunkcije, raka i fibroze | |
| TW202313050A (zh) | 組合療法 | |
| JP2014144916A (ja) | ２−アシルアミノチアゾール化合物の結晶 | |
| JP2024544660A5 (https=) |